Compare Ascendis Pharma A/S (ASND) vs Clorox Co (CLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Clorox Co — how do they compare? Ascendis Pharma A/S trades at $257.44 (market cap $16.67B), while Clorox Co trades at $106.96 (market cap $13.09B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Clorox Co pays a 4.62% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CLX | |
|---|---|---|
Market Cap | $16.67B | $13.09B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $127.16 |
52-Week Low | $189.74 | $86.12 |
Enterprise Value | $17.04B | $18.47B |
Dividend Yield | — | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Clorox (CLX) trades at $107.70, up 2.43% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations, though Q4 2025 missed. The company maintains solid profitability with a net margin of 8.74% and ROE of 285.64%, but faces high P/B of 145.45. News highlights Q4 sales beat and a dividend increase to $1.25 per share, while inflation and consumer value-seeking pose challenges.
Outlook is mixed: improving market share and strategic initiatives support growth, but inflation and competitive pressures risk margins. Analyst consensus is cautious with a hold-heavy rating and $97.50 price target below current levels. Key risks include supply-chain inflation and weak organic sales, requiring careful monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
